From Half-Life to Full-Life.
Full-Life Technologies Limited (“Full-Life”) is a fully integrated RadioTherapeutics company with offices in China, Europe, and the US.
Global management team with decades of experience spanning the discovery, development, production, and logistics of radiopharmaceuticals.About our team
We attach the radionuclide to the targeting vector (single domain antibody or peptide) which delivers the payload directly to the tumor.About our pipeline
Our radiotechnology platform takes a wholistic approach covering production and logistics of radiopharmaceutical drug products.About our technology
Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
Nov 29, 2022
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
Aug 10, 2022
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board